New FDA Documents Defining the Path for Cell and Gene Therapy CMC

I have been paying more attention to gene therapy lately, as some of my clients are in that space. Between April and June, the FDA published three documents that significantly impact the CMC and analytical map for cell and gene therapy. The Safety Assessment of Genome Editing using NGS draft guidance came out in April, the Chemistry, Manufacturing, and Controls Flexibilities for CGT BLAs final guidance was issued in May, and Leveraging Prior Knowledge draft for genome editing products followed on June 2. Together, they hint at the regulatory framework sponsors will be operating in for the next decade.

One: CMC Flexibilities for CGT BLAs

The May final guidance, FDA-2026-D-4692, is the most immediately consequential communication of the three because it is effective now. It applies flexibility to CMC expectations across the development arc of any Cell and Gene Therapy (CGT) BLA.

During clinical development, FDA confirms phase-appropriate CGMP and Part 211 exemption for Phase 1 material. Release criteria can be permissive in early phase, but numerical criteria must be predefined before Phase 2 or 3. Comparability for minor manufacturing changes can be supported with limited data when it poses a low risk to product quality.

For process validation, FDA states there is no minimum number of PPQ batches in 21 CFR 601.20 or the CGMP regulations. The number is justified based on product and process understanding. Concurrent release of PPQ batches post-licensure is permitted when PPQ production limitations exist.

For commercial specifications, the guidance acknowledges that small patient populations yield small lot counts at BLA submission. Analytical method validation using a single representative lot may be acceptable with adequate support. Post-approval reevaluation of acceptance criteria can be agreed to in advance via prior approval supplement. Stability data from representative clinical lots can support shelf life, and stability data from similar products may set initial stability periods. Alternative analytical methods, including rapid microbiological methods, can replace compendial methods when validated for the intended use.

Used well, this is a structured set of flexibilities that takes meaningful time and cost out of a BLA package.

Two: Leveraging Prior Knowledge for Gene Therapy Products

The June draft narrows the focus to genome editing and defines what kinds of data can be reused across programs. It distinguishes public knowledge (ICH, USP, EP, peer reviewed literature) from platform knowledge (internal company work, CDMO master files, consortium data).

The most useful concept in the document is the distinction between independent and dependent attributes. Methods, stability infrastructure, and process parameters are typically independent of the specific product, which makes them easier to leverage. Potency, identity, and product specific safety are dependent. Sort your CQA list against this lens first.

Platform analytical methods can be qualified once and applied to similar components, with product specific verification limited to the attributes most affected by differences. gRNAs that differ only in spacer sequence can share lot release specifications. Stability data on one mRNA encoded nuclease can support early phase claims on another. Comparability data for a reagent change on one gRNA can support the same change on a similar gRNA. Platform PPQ data can justify a reduced number of new PPQ batches.

One detail worth knowing: for BLAs, drug substance, intermediate, and drug product information must be in the application itself under 21 CFR 601.2. Master files can be referenced for INDs but cannot substitute for direct inclusion at BLA.

Three: NGS Safety Assessment for Gene Therapy Products

The April guidance sets the standard for the safety call the prior knowledge guidance will not let you transfer. Off-target editing and chromosomal integrity must be evaluated using NGS, with bioinformatics supported by published data or in-house engineering runs, and sequencing depth adequate to detect events below the on target edit rate.

The guidance is explicit on points sponsors have been handling inconsistently. Modality matters: assays for double strand breaks may not pick up base editor nicks. Sample selection matters: ex-vivo studies should use the same cell type at on-target rates comparable to the drug product. In vivo studies should match the clinical delivery method when feasible.

Human genetic variation is now its own analytical question. For diseases with characterized prevalence, in silico off-target assessment should account for population variants from public databases. For ultra rare and single patient indications, this analysis can be deferred with FDA discussion. Chromosomal integrity assessment is recommended for editors creating double strand breaks, with additional assessment for translocations between on target and confirmed off target sites.

All off-target and chromosomal translocation studies should be completed before the original IND, with INTERACT or pre-IND engagement on the strategy.

How They Fit

Taken together these three documents tell sponsors a consistent story. FDA will grant meaningful flexibility on PPQ batches, method validation, commercial specifications, and leverageable platform data. FDA is unlikely to grant flexibility on safety-related issues.

Practical Takeaways

First, build an inventory of leverageable platform data now. The CMC flexibilities and prior knowledge guidances both reward documentation written with leveraging in mind. Map your analytical methods, stability infrastructure, and process knowledge against the independent versus dependent attribute test.

Second, request an INTERACT or pre-IND meeting before committing to a leveraging proposal or an off target assessment strategy of any consequence. All three guidances recommend it.

If you are working in CGT against this new regulatory landscape and want a second set of eyes on your analytical and CMC strategy, I am happy to talk.

Sources:

- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients (Press Announcement, June 2026) — FDA

- Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing (Draft Guidance, June 2026, Docket FDA-2026-D-1257) — FDA / CBER

- Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application (Final Guidance, May 2026, Docket FDA-2026-D-4692) — FDA / CBER

- Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing (Draft Guidance, April 2026) — FDA / CBER